Lupin's Diabetes Portfolio Expands with Acquisition of Germany's GmbH, Including Ondero and Ondero Met

18 Aug, 2023

Lupin's Diabetes Portfolio Expands with Acquisition of Germany's GmbH, Including Ondero and Ondero Met

Lupin Ltd, a prominent global pharmaceutical company, has successfully acquired the brand names Ondero and Ondero Met from Boehringer Ingelheim, a German pharmaceutical company. The acquisition was finalized on August 18.

Lupin revealed that it completed the procurement of these brands through a deed of assignment established last year with Boehringer Ingelheim International GmbH, based in Germany. This acquisition encompasses not only the brands but also the associated trademark rights for Ondero and Ondero Met, which are related to diabetes treatments.

Having co-marketed both brands in the Indian market since 2015 under a partnership with Boehringer Ingelheim India, the Mumbai-based multinational pharmaceutical firm has taken this step to expand its diabetes portfolio within India. As highlighted in an official filing, India has approximately 77 million adults aged 18 and above with Type-2 Diabetes, along with nearly 25 million individuals at a pre-diabetic stage, putting them at higher risk for future diabetes development. Both Ondero (Linagliptin) and Ondero Met (Linagliptin + Metformin) are considered the gold standards in diabetes management.

Lupin's acquisition reflects its dedication to enhancing patient care options, particularly in the realm of diabetes treatment. Nilesh Gupta, the Managing Director of Lupin, emphasized that this acquisition reinforces the company's commitment to providing quality pharmaceuticals and solidifies its position as a leader in the anti-diabetes sector.

Rajeev Sibal, President of India Region Formulations at Lupin, stressed the escalating burden of diabetes due to factors like obesity and unhealthy lifestyles. He expressed that the acquisition aligns with Lupin's mission to empower healthcare professionals to combat diabetes effectively and enhance the lives of those affected by this challenging condition.

Following the announcement of the brand acquisition, Lupin's shares experienced a 2% decline in value by the end of trading on August 17. On the previous day, the pharmaceutical company had reached a 52-week high with shares priced at Rs 1,143.70 each.